Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

European Journal of Paediatric Neurology, published by Elsevier Science Ltd, is a premier academic journal dedicated to advancing the field of paediatric neurology. With its ISSN 1090-3798 and E-ISSN 1532-2130, this journal serves as a vital resource for researchers, clinicians, and students alike, focusing on the latest findings and innovative treatments in paediatric neurological disorders. The journal has established itself as a leading publication in its field, achieving a Q1 classification in Pediatrics, Perinatology and Child Health, and holding a reputable Q2 status in Clinical Neurology as of 2023. Positioned within the top 88th percentile in Pediatrics and the 76th percentile in Clinical Neurology according to Scopus ranks, it publishes rigorous peer-reviewed articles that contribute significantly to clinical practice and research. Although not open access, the journal provides vital insights into the complexities of neurological conditions affecting the pediatric population, making it an essential tool for scholars and professionals striving to improve child health outcomes. With a publication trajectory spanning from 1997 to 2024, it continues to be at the forefront of paediatric neurological research, inspiring innovation and collaboration in the scientific community.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

Ideggyogyaszati Szemle-Clinical Neuroscience, an esteemed publication under the auspices of LITERATURA MEDICA, serves as a pivotal platform in the field of neurology and clinical neuroscience. Established in Hungary, this journal has been committed to advancing the understanding of neurological disorders and treatments since its inception. With its ISSN 0019-1442 and E-ISSN 2498-6208, it provides a unique local perspective alongside valuable contributions to the global discourse in neuroscience. Despite earning a Q4 quartile ranking in both Neurology and Clinical Neurology, the journal remains dedicated to publishing high-quality research that contributes to the scientific community's collective knowledge. Its coverage spans significant converged years from 1954 to 1985 and now continues through 2024, reflecting a rich historical foundation. Recognizing the importance of open access, the journal strives to enhance accessibility, albeit currently lacking a formal open-access model. Researchers, professionals, and students in the field will find in Ideggyogyaszati Szemle a resource vital for keeping abreast of emerging trends and findings in neurological science.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

The Journal of Movement Disorders, published by the Korean Movement Disorders Society, is a premier open access journal dedicated to advancing the field of neurology with a specific focus on movement disorders. Established in 2008 and indexed with ISSN 2005-940X and E-ISSN 2093-4939, this journal plays a vital role in disseminating high-quality research and clinical insights to a global audience. With an impressive Q2 ranking in both Neurology and Clinical Neurology categories for 2023, the journal continues to feature innovative research articles that contribute to better understanding and management of various movement disorders. Ranked 104th out of 400 in Clinical Neurology and 54th out of 192 in Neuroscience, the Journal of Movement Disorders offers an essential platform for researchers, healthcare professionals, and students alike, fostering collaboration and knowledge exchange in a rapidly evolving field.

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.

PARKINSONISM & RELATED DISORDERS, published by Elsevier Science Ltd, is a prominent peer-reviewed journal dedicated to advancing the understanding of Parkinson's disease and related neurodegenerative disorders. With an impact factor placing it in the Q2 category across multiple fields including Geriatrics and Gerontology and Neurology for 2023, this journal serves as a crucial platform for researchers, healthcare professionals, and students alike. Covering an array of topics from clinical trials to innovative therapeutic strategies, it aims to disseminate valuable insights that can improve patient care and outcomes. While it remains a subscription-based journal, its relevance is underscored by its consistent rankings in Scopus, where it ranks 105th in Clinical Neurology and 35th in Geriatrics and Gerontology. Authored by top scholars in the field, PARKINSONISM & RELATED DISORDERS continues to contribute significantly to the body of knowledge surrounding these debilitating conditions, facilitating the exchange of cutting-edge research and fostering collaboration within the scientific community.